Early inflammatory arthritis versus rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 21, Issue 2, 2009, Pages 118-123

  Finckh, Axel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Early diagnosis; Early disease; Prevention trial; Rheumatoid arthritis; Undifferentiated arthritis

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE;

ARTHRITIS; COMPARATIVE STUDY; DISEASE COURSE; DRUG WITHDRAWAL; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK PATIENT; HUMAN; INFLAMMATORY DISEASE; JOINT INJURY; PATHOGENESIS; PATHOPHYSIOLOGY; POLYARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INFLAMMATION; MALE; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 62449100170     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283235ac4     Document Type: Review

References (32)

1. Weisman MH. Progress toward the cure of rheumatoid arthritis? The Best study. Arthritis Rheum 2005; 52:3326-3332.
2. Fautrel B, Clarke AE, Guillemin F, et al. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective. J Rheumatol 2005; 32:443-453.
3. van Dongen H, van Aken J, Lard LR, etal. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56:1424-1432. This randomized controlled trial analyzes the benefits of limited course of methotrexate in patients with early undifferentiated arthritis.
4. McColl GJ, Szer J, Wicks IP. Sustained remission, possibly cure, of seronegative arthritis after high-dose chemotherapy and syngeneic hematopoietic stem cell transplantation. Arthritis Rheum 2005; 52:3322.
5. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:27-35.
6. Finckh A, Liang MH, van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006; 55:864-872.
7. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867-875.
8. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.
9. Pedersen M, Jacobsen S, Garred P, et al. Strong combined gene-environment effects in anticyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007; 56:1446-1453.
10. Kallberg H, Jacobsen S, Bengtsson C, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis 2008. doi: 10.1136/ ard.2007.086314 [Epub ahead of print].
11. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum 2008; 59:302-310.
12. Pikwer M, Bergstrom U, Nilsson JA, et al. Breast-feeding, but not oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis 2008. doi: 10.1136/ard.2007.084707.
13. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.
14. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749.
15. Koivula MK, Heliovaara M, Ramberg J, et al. Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis 2007; 66:1450-1455.
16. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008; 67:801-807.
17. Deane KD, Robinson WH, Majka DS, et al. Rheumatoid arthritis (RA)-related antibody positivity is associated with serum cytokine elevations in RA-free first-degree relatives (FDRs) of RA-probands. ACR Annual Scientific Meeting 2008; San Francisco: Arthritis Rheum; 2008, p. 1203.
18. Vossenaar ER, Smeets TJ, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50:3485-3494.
19. Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum 2003; 48:2701-2705.
20. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994; 15:115-120.
21. Feldman DE, Bernatsky S, Haggerty J, et al. Delay in consultation with specialists for persons with suspected new-onset rheumatoid arthritis: a population-based study. Arthritis Rheum 2007; 57:1419-1425.
22. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56:433-440. Authors validate a new clinical prediction rule of RA in patients presenting with undifferentiated arthritis.
23. Chan KW, Felson DT, Yood RA, et al. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994; 37:814-820.
24. Harrison BJ, Symmons DP, Barrett EM, et al. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998; 25:2324-2330.
25. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797-808. This large meta-analysis confirms that presence of anti-CCP antibodies is more specific than rheumatoid factor for diagnosing rheumatoid arthritis
26. Liao KP, Batra KL, Chibnik L, et al. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008; 67:1557-1561.
27. Finckh A, Liang MH. Anticyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: bayes clears the haze. Ann Intern Med 2007; 146:816-817.
28. van Der Helm-van Mil AH, Detert J, Cessie SL, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58:2241-2247. The accuracy of the Leiden prediction rule is confirmed in several independent cohorts of patients with undifferentiated arthritis.
29. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCI-SIT). Ann Rheum Dis 2007; 66:34-45.
30. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
31. Verstappen SMM, McCoy MJ, Roberts C, et al. A 3 week course of IM steroids injections may prevent the progression of very early inflammatory polyarthritis: results of the STIVEA trial [abstract OP-0041]. EULAR: Annual European Congress of Rheumatology 2008; Paris: Ann Rheum Dis; 2008. p. 61. This abstract summarizes a randomized controlled trial with a limited course of i.m. steroids in patients with early undifferentiated arthritis.
32. Emery P, Durez P, Dougados M, et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [abstract OP-0130]. Annual European Congress of Rheumatology 2008; Paris: Ann Rheum Dis; 2008. p. 89. This abstract summarizes a randomized controlled trial with a limited course (6 months) of abatacept in patients with early undifferentiated arthritis.